Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study
Allergan’s (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.
Source:: https://finance.yahoo.com/news/allergan-apos-second-anti-cgrp-141402769.html
